Benitec Submits IND for HCV Drug | GenomeWeb

Benitec Biopharma announced this week that it has submitted an investigational new drug application to begin phase I/IIa testing of its expressed RNAi-based hepatitis C treatment TT-034.

TT-034 expresses shRNAs targeting three portions of the HCV genome. It was originally developed by Benitec, but financial problems led the company to license the agent to startup Tacere Therapeutics in 2006.

Benitec acquired Tacere last year, reacquiring the HCV program. It expects to begin human testing of TT-034 early next year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.